Hypersensitivity reactions
Few cases were reported: one with a morbiliform eruption and exfoliative dermatitis due to ruxolitinib (156), another one with palmoplantar pustulosis due to baricitinib (157), and cases of acute urticaria (158) and palmoplantar pustulosis (159) due to tofacitinib.